A. Nafziger

发表

Comparison of midazolam and simvastatin as cytochrome P450 3A probes

D. Kazierad, E. Chung, A. Nafziger, 2006, Clinical pharmacology and therapeutics.

Reliability and changes in validity of self-reported cardiovascular disease risk factors using dual response: the behavioral risk factor survey.

S. Bowlin, A. Nafziger, B. D. Morrill, 1996, Journal of Clinical Epidemiology.

A warfarin‐dosing model in Asians that uses single‐nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9

Ling-Zhi Wang, Richie Soong, B. Goh, 2006, Clinical pharmacology and therapeutics.

Validity of cardiovascular disease risk factors assessed by telephone survey: the Behavioral Risk Factor Survey.

S. Bowlin, P. Jenkins, A. Nafziger, 1993, Journal of clinical epidemiology.

Sildenafil Treatment of Antidepressant-Induced Sexual Dysfunction

A. Nafziger, 2013 .

Lack of effect of subject posture on intravenous midazolam clearance: implications for hepatic cytochrome P450 3A phenotyping.

Joseph D. Ma, A. Nafziger, J. Bertino, 2009, British journal of clinical pharmacology.

Dissecting the ``black box' ' of community intervention: Lessons from community-wide cardiovascular disease prevention programs in the US and Sweden

L. Weinehall, T. Pearson, S. Wall, 2001, Scandinavian journal of public health. Supplement.

Inherent Dangers of Using Non–US Food and Drug Administration–Approved Substances of Abuse

C. White, A. Nafziger, Thom Browne, 2021, Journal of clinical pharmacology.

The not so "ideal" body weight-based dosing of Integrilin in obesity.

A. Nafziger, J. Bertino, M. Pai, 2012, American heart journal.

Evaluation of inhibitory drug interactions during drug development: Genetic polymorphisms must be considered

A. Nafziger, J. Bertino, Lois S. Lee, 2005, Clinical pharmacology and therapeutics.

Different outcomes for different interventions with different focus!— A cross-country comparison of community interventions in rural Swedish and US populations

L. Weinehall, S. Wall, P. Jenkins, 2001, Scandinavian journal of public health. Supplement.

Effects of Oral Vitamin K on S‐ and R‐Warfarin Pharmacokinetics and Pharmacodynamics: Enhanced Safety of Warfarin as a CYP2C9 Probe

A. Rettie, A. Gaedigk, A. Nafziger, 2001, Journal of clinical pharmacology.

Effect of Grapefruit Juice on Clarithromycin Pharmacokinetics

C. Peloquin, A. Nafziger, G. Amsden, 1998, Antimicrobial Agents and Chemotherapy.

Drug-Metabolizing Enzyme Inhibition by Ketoconazole Does Not Reduce Interindividual Variability of CYP3A Activity as Measured by Oral Midazolam

A. Nafziger, J. Bertino, Maylee Chen, 2006, Drug Metabolism and Disposition.

Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping.

A. Nafziger, J. Bertino, R. Kulawy, 2001, Pharmacogenetics.

Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques

D. Greenblatt, E. Choo, G. Wilkinson, 2002, Journal of clinical pharmacology.

Single Plasma Concentrations of 1′‐Hydroxymidazolam or the Ratio of 1′‐Hydroxymidazolam: Midazolam Do Not Predict Midazolam Clearance in Healthy Subjects

E. Choo, G. Wilkinson, A. Kashuba, 2002, Journal of clinical pharmacology.

Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity.

S. Gotzkowsky, A. Kashuba, Ya-Chi Chen, 2006, British journal of clinical pharmacology.

Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin

A. Gaedigk, J. Kirchheiner, A. Kashuba, 2006, European Journal of Clinical Pharmacology.

Effect of a Triphasic Oral Contraceptive on Drug‐Metabolizing Enzyme Activity as Measured by the Validated Cooperstown 5+1 Cocktail

E. Sellers, G. Kearns, A. Gaedigk, 2005, Journal of clinical pharmacology.

Limited Sampling Strategy of S‐Warfarin Concentrations, but Not Warfarin S/R Ratios, Accurately Predicts S‐Warfarin AUC during Baseline and Inhibition in CYP2C9 Extensive Metabolizers

A. Gaedigk, A. Kashuba, A. Nafziger, 2004, Journal of clinical pharmacology.

Combined phenotypic assessment of cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A, N‐acetyltransferase‐2, and xanthine oxidase activities with the “Cooperstown 5+1 cocktail”

E. Sellers, G. Kearns, A. Gaedigk, 2003, Clinical pharmacology and therapeutics.

Longitudinal changes in dehydroepiandrosterone concentrations in men and women.

S. Bowlin, P. Jenkins, A. Nafziger, 1998, The Journal of laboratory and clinical medicine.

Cardiovascular risk factor burden has a stronger association with self-rated poor health in adults in the US than in Sweden, especially for the lower educated

L. Weinehall, M. Emmelin, H. Stenlund, 2006, Scandinavian journal of public health.

Comparative Pharmacokinetics and Pharmacodynamic Target Attainment of Ertapenem in Normal-Weight, Obese, and Extremely Obese Adults

G. Drusano, A. Nafziger, J. Bertino, 2006, Antimicrobial Agents and Chemotherapy.

Oral Cimetidine Prolongs Clarithromycin Absorption

C. Peloquin, A. Nafziger, G. Amsden, 1998, Antimicrobial Agents and Chemotherapy.

The Otsego-Schoharie healthy heart program: prevention of cardiovascular disease in the rural US

P. Jenkins, A. Nafziger, C. Lewis, 2001, Scandinavian journal of public health. Supplement.

Newly Diagnosed Type 2 Diabetics Have The Lowest Body Mass Index Change Among Rural Populations Of Sweden And The United States

L. Weinehall, H. Stenlund, T. Pearson, 2005 .

Lack of Effect of Zafirlukast on the Pharmacokinetics of Azithromycin, Clarithromycin, and 14-Hydroxyclarithromycin in Healthy Volunteers

K. Garey, C. Peloquin, A. Nafziger, 1999, Antimicrobial Agents and Chemotherapy.

A Study of the Pharmacokinetics of Azithromycin and Nelfinavir When Coadministered in Healthy Volunteers

G. Foulds, A. Nafziger, G. Amsden, 2000, Journal of clinical pharmacology.

Desirudin Dosing and Monitoring in Moderate Renal Impairment

A. Nafziger, J. Bertino, 2010, Journal of clinical pharmacology.

Self-reported physical activity in a rural county: a New York county health census.

C. Eaton, D. Strogatz, A. Nafziger, 1994, American journal of public health.

The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Oliceridine

F. Skobieranda, A. Nafziger, M. Fossler, 2019, Clinical pharmacology in drug development.

Absence of Tobramycin Pharmacokinetic and Creatinine Clearance Variation During the Menstrual Cycle: Implied Absence of Variation in Glomerular Filtration Rate

A. Nafziger, J. Bertino, M. Schwartzman, 1989, Journal of clinical pharmacology.

Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions

O. Naderer, A. Nafziger, J. Bertino, 1997, Antimicrobial agents and chemotherapy.

Aminoglycoside dosing weight correction factors for patients of various body sizes

A. Traynor, A. Nafziger, J. Bertino, 1995, Antimicrobial agents and chemotherapy.

A. Nafziger, J. Bertino, 2004, European Journal of Clinical Pharmacology.

Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism.

A. Nafziger, J. Bertino, T. Jennings, 1993, The Journal of laboratory and clinical medicine.

Design issues in the combination of international data from two rural community cardiovascular intervention programs

L. Weinehall, S. Wall, P. Jenkins, 2001, Scandinavian journal of public health. Supplement.

Quantitation of three‐month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N‐acetyltransferase‐2, and xanthine oxidase activity determined with caffeine phenotyping

G. Kearns, J. Leeder, A. Kashuba, 1998, Clinical pharmacology and therapeutics.

The Norsjö-Cooperstown healthy heart project: A case study combining data from different studies without the use of meta-analysis

L. Weinehall, P. Jenkins, T. Pearson, 2001, Scandinavian journal of public health. Supplement.

Cisapride: A potential model substrate to assess cytochrome P4503A4 activity in vivo

E. Schuetz, G. Kearns, J. Leeder, 2003, Clinical pharmacology and therapeutics.

Evaluation of In Vivo P-Glycoprotein Phenotyping Probes

Joseph D. Ma, A. Nafziger, J. Bertino, 2010, Clinical pharmacokinetics.

Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping

G. Kearns, R. Ellis, A. Gaedigk, 1999, Clinical pharmacology and therapeutics.

Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping.

G. Kearns, A. Gaedigk, J. Leeder, 1998, Pharmacogenetics.

Limitations of dextromethorphan N-demethylation as a measure of CYP3A activity.

G. Kearns, A. Gaedigk, J. Leeder, 1999, Pharmacogenetics.

Maribavir Pharmacokinetics and the Effects of Multiple-Dose Maribavir on Cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults

A. Gaedigk, Joseph D. Ma, A. Nafziger, 2006, Antimicrobial Agents and Chemotherapy.

Is it sex or is it gender?

A. Nafziger, J. S. Kim, Jooran S. Kim, 2000, Clinical pharmacology and therapeutics.

Core Entrustable Professional Activities in Clinical Pharmacology for Entering Residency: Common Problem Drugs and How to Prescribe Them

B. Meibohm, M. Mandić, J. N. van den Anker, 2019, Journal of clinical pharmacology.

Dehydroepiandrosterone and dehydroepiandrosterone sulfate: their relation to cardiovascular disease.

T. Bush, T. Bush, A. Nafziger, 1991, Epidemiologic reviews.

Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response.

G. Drusano, H. Keyserling, C. Harro, 2003, Vaccine.

Prediction of response to hepatitis B vaccine in health care workers: whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness?

J. Murray, A. Nafziger, J. Bertino, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A Dose‐Ranging Study of Gentamicin Pharmacokinetics: Implications for Extended Interval Aminoglycoside Therapy

D. Mcnamara, A. Nafziger, J. Bertino, 2001, Journal of clinical pharmacology.

Pharmacokinetics in Serum and Leukocyte Exposures of Oral Azithromycin, 1,500 Milligrams, Given over a 3- or 5-Day Period in Healthy Subjects

G. Foulds, A. Nafziger, G. Amsden, 1999, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics of oral fleroxacin in male and premenopausal female volunteers

A. Nafziger, J. Bertino, 1996, Antimicrobial agents and chemotherapy.

Effect of a fat- and calcium-rich breakfast on pharmacokinetics of fleroxacin administered in single and multiple doses

A. Nafziger, J. Bertino, M. Wong, 1994, Antimicrobial Agents and Chemotherapy.

Design issues in the combination of international data from two rural community cardiovascular intervention programs

L. Weinehall, S. Wall, P. Jenkins, 2001 .

Poor Correlation Between 24 hr Urinary 6β‐Hydroxy Cortisol: Cortisol Molar Ratios (CMR) and Plasma Midazolam Clearance (MDZ CL) as Measures of Hepatic CYP3A Activity

A. Kashuba, A. Nafziger, M. Rocci, 1999 .

Incidence of sexual dysfunction in healthy volunteers on fluvoxamine therapy.

A. Nafziger, J. Bertino, A. Kashuba, 1999, The Journal of clinical psychiatry.

Clinical relevance of reducing triglycerides. Implications for ischaemic heart disease treatment.

A. Nafziger, 1994, Drugs.

S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction

L. Lewis, A. Kashuba, Joseph D. Ma, 2016, Therapeutic drug monitoring.

Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker

E. Sellers, A. Gaedigk, A. Nafziger, 2002, Clinical pharmacology and therapeutics.

Back to the future: using aminoglycosides again and how to dose them optimally.

G. Drusano, S. Bhavnani, P. Ambrose, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing

A. Nafziger, J. Bertino, D. Demczar, 1997, Antimicrobial agents and chemotherapy.

Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients.

A. Nafziger, J. Bertino, M. Karl, 2000, Archives of internal medicine.

Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults

D. Yim, E. Capparelli, O. Yin, 2018, Therapeutic drug monitoring.

Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring.

A. Nafziger, J. Bertino, J. Bertino, 1993, The Journal of infectious diseases.

Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.

A. Nafziger, J. Bertino, J. F. Rogers, 2002, The American journal of medicine.

Application of Bayes Theorem to Aminoglycoside‐Associated Nephrotoxicity: Comparison of Extended‐Interval Dosing, Individualized Pharmacokinetic Monitoring, and Multiple‐Daily Dosing

A. Nafziger, J. Bertino, T. Erb, 2004, Journal of clinical pharmacology.

Optimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria

G. Drusano, A. Kashuba, A. Nafziger, 1999, Antimicrobial Agents and Chemotherapy.

Effect of Terbinafine on Theophylline Pharmacokinetics in Healthy Volunteers

A. Nafziger, G. Amsden, E. Trépanier, 1998, Antimicrobial Agents and Chemotherapy.

Absence of Effect of Terbinafine on the Activity of CYP1A2, NAT‐2, and Xanthine Oxidase

G. Kearns, A. Kashuba, A. Nafziger, 1998, Journal of clinical pharmacology.

Dosing of Aminoglycosides To Rapidly Attain Pharmacodynamic Goals and Hasten Therapeutic Response by Using Individualized Pharmacokinetic Monitoring of Patients with Pneumonia Caused by Gram-Negative Organisms

A. Nafziger, J. Bertino, A. Kashuba, 1998, Antimicrobial Agents and Chemotherapy.

in single and multiple doses . pharmacokinetics of fleroxacin administered Effect of a fat-and calcium-rich breakfast on

A. Nafziger, J. Bertino, M. Wong, 2022 .

Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.

A. Nafziger, J. Bertino, D. Streetman, 2000, Pharmacogenetics.

Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N‐acetyltransferase‐2, and xanthine oxidase with the “Cooperstown cocktail”

Andrea Gaedigk, G. Kearns, A. Gaedigk, 2000, Clinical pharmacology and therapeutics.

Pharmacological Differences between Men and Women

M. J. Berg, A. Nafziger, J. Bertino, 2007 .

Lack of effect of atenolol and nadolol on the metabolism of theophylline.

A. Nafziger, J. Bertino, J. Pieper, 1990, British journal of clinical pharmacology.

Randomized Study of Paclitaxel and Tamoxifen Deposition into Human Brain Tumors: Implications for the Treatment of Metastatic Brain Tumors

M. Desai, R. Goodman, G. Mckhann, 2006, Clinical Cancer Research.

Physiological Changes During the Menstrual Cycle and Their Effects on the Pharmacokinetics and Pharmacodynamics of Drugs

A. Kashuba, A. Nafziger, Angela D. M. Kashuba, 1998, Clinical pharmacokinetics.

The Absolute Bioavailability of Oral Melatonin

J S Bertino, D. Blask, D E Blask, 2000, Journal of clinical pharmacology.

Individualized Pharmacokinetic Monitoring Results in Less Aminoglycoside‐Associated Nephrotoxicity and Fewer Associated Costs

C. Destache, A. Nafziger, J. Bertino, 2001, Pharmacotherapy.

Investigation of bioequivalence and tolerability of intramuscular ceftriaxone injections by using 1% lidocaine, buffered lidocaine, and sterile water diluents

A. Nafziger, J. Bertino, S. Kohlhepp, 1996, Antimicrobial agents and chemotherapy.

Opioid Therapy in Acute and Chronic Pain

R. Barkin, A. Nafziger, 2018, Journal of clinical pharmacology.

Sex differences in CYP3A activity using intravenous and oral midazolam

G. Drusano, A. Nafziger, J. Bertino, 2006, Clinical pharmacology and therapeutics.

Drugs of Abuse: How Clinical Pharmacology Brings Clarity to the Shadows

A. Nafziger, C. M. White, C. M. White, 2021, Journal of clinical pharmacology.

Genetic Polymorphisms of Cytochrome P450 Enzymes and the Effect on Interindividual, Pharmacokinetic Variability in Extensive Metabolizers

Joseph D. Ma, A. Nafziger, J. Bertino, 2004, Journal of clinical pharmacology.

Variation in the pharmacokinetics of gentamicin and tobramycin in patients with pleural effusions and hypoalbuminemia

J. V. Etzel, A. Nafziger, J. Bertino, 1992, Antimicrobial Agents and Chemotherapy.

Variation inthePharmacokinetics ofGentamicin andTobramycin in Patients withPleural Effusions andHypoalbuminemia

A. Nafziger, J. Bertino, 1992 .

Utility and Application of Urine Drug Testing in Chronic Pain Management With Opioids

A. Nafziger, J. Bertino, 2009, The Clinical journal of pain.

Simplified Estimation of Aminoglycoside Pharmacokinetics in Underweight and Obese Adult Patients

A. Nafziger, J. Bertino, M. Pai, 2011, Antimicrobial Agents and Chemotherapy.

Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping

G. Kearns, J. Leeder, A. Kashuba, 1998, Clinical pharmacology and therapeutics.

Evaluation of the Drug Interaction Potential of Aplaviroc, a Novel Human Immunodeficiency Virus Entry Inhibitor, Using a Modified Cooperstown 5 + 1 Cocktail

S. Piscitelli, K. Adkison, B. Johnson, 2006, Journal of clinical pharmacology.

Validating Phenotyping Cocktails: More Work Needs to Be Done

Joseph D. Ma, A. Nafziger, J. Bertino, 2012, Journal of clinical pharmacology.

Clinical Relevance of Reducing Triglycerides

A. Nafziger, 1994, Drugs.

Relative abundance of organochlorine pesticides and polychlorinated biphenyls in adipose tissue and serum of women in Long Island, New York.

S D Stellman, M. Citron, M. Kemeny, 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Lack of Weight‐Based Dose Dependency and Intraindividual Variability of Omeprazole for CYP2C19 Phenotyping

E. Sellers, A. Gaedigk, A. Nafziger, 2004, Journal of clinical pharmacology.

Limited Sampling Models for Oral Midazolam: Midazolam Plasma Concentrations, Not the Ratio of 1‐Hydroxymidazolam to Midazolam Plasma Concentrations, Accurately Predicts AUC as a Biomarker of CYP3A Activity

A. Nafziger, J. Bertino, Lois S Lee, 2006, Journal of clinical pharmacology.

Self-rated health does not predict 10-year weight change among middle-aged adults in a longitudinal population study

M. Emmelin, G. Lönnberg, P. Jenkins, 2011, BMC public health.

Dissecting the ``black box' ' of community intervention: background and rationale

L. Weinehall, S. Wall, P. Jenkins, 2001, Scandinavian journal of public health. Supplement.

A population perspective on obesity prevention : lessons learned from Sweden and the U.S.

A. Nafziger, 2006 .

Effect of fluvastatin on CYP2C9 activity using warfarin as a probe

A. Gaedigk, J. Kirchheiner, S. Bauer, 2004 .

Seasonal influenza vaccination and technologies

A. Nafziger, D. Pratt, 2014, Journal of clinical pharmacology.

Probe Cocktail Studies

A. Nafziger, J. Bertino, 2011 .

Use of Omeprazole as a CYP3A Probe Drug: Effect of Sex and Menstrual Cycle Phase on CYP3A Activity in Healthy Caucasian Adults

E. Sellers, A. Nafziger, J. Bertino, 2006, Journal of clinical pharmacology.

DURATION OF PLECONARIL EFFECT ON CYTOCHROME P450 3A ACTIVITY IN HEALTHY ADULTS USING THE ORAL BIOMARKER MIDAZOLAM

G. Rhodes, Joseph D. Ma, A. Nafziger, 2006, Drug Metabolism and Disposition.

Lack of effect of dirithromycin on theophylline pharmacokinetics in healthy volunteers.

A. Nafziger, G. Amsden, S. McConnell, 1999, The Journal of antimicrobial chemotherapy.

Quantification of 3‐month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam

A. Kashuba, A. Nafziger, J. Bertino, 1998, Clinical pharmacology and therapeutics.

High obesity incidence in northern Sweden: How will Sweden look by 2009?

L. Weinehall, H. Stenlund, T. Pearson, 2006, European Journal of Epidemiology.

An evaluation of the atkins' diet.

Bernard V. Miller, A. Nafziger, J. Bertino, 2003, Metabolic syndrome and related disorders.

Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probe.

T. Fullerton, P. Snyder, N. Lawendy, 2009, International journal of clinical pharmacology and therapeutics.

Endogenous 4β-Hydroxycholesterol-to-Cholesterol Ratio Is Not a Validated Biomarker for the Assessment of CYP3A Activity

Joseph D. Ma, A. Nafziger, J. Bertino, 2013, Drug Metabolism and Disposition.

Inhibition of Theophylline Elimination by Diltiazem Therapy

John J. May, A. Nafziger, J. Bertino, 1987, Journal of clinical pharmacology.

S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults

E. Capparelli, A. Kashuba, Joseph D. Ma, 2021, European Journal of Clinical Pharmacology.

Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.

Ronald N. Jones, G. Drusano, F. Sörgel, 2010, Diagnostic microbiology and infectious disease.

Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach

H. Greenberg, E. Capparelli, Joseph D. Ma, 2018, Journal of clinical pharmacology.

Limitations of S-warfarin truncated area under the concentration-time curve to predict cytochrome P450 2c9 activity.

Joseph D. Ma, A. Nafziger, J. Bertino, 2012, Drug metabolism letters.

Population Pharmacokinetic Analyses for Ertapenem in Subjects with a Wide Range of Body Sizes

C. Landersdorfer, S. Bhavnani, A. Forrest, 2018, Antimicrobial Agents and Chemotherapy.

Distribution of Orthopaedic Surgeons, Lawyers, and Malpractice Claims in New York

M. Ries, A. Nafziger, J. Bertino, 1997, Clinical orthopaedics and related research.

The Effect of Oral Pleconaril on Hepatic Cytochrome P450 3A Activity in Healthy Adults Using Intravenous Midazolam as a Probe

G. Rhodes, Joseph D. Ma, A. Nafziger, 2006, Journal of clinical pharmacology.

Who is maintaining weight in a middle-aged population in Sweden? A longitudinal analysis over 10 years

L. Weinehall, H. Stenlund, T. Pearson, 2007, BMC public health.

Prediction of midazolam (MDZ) clearance (CL) using minimized sampling (MS) of 1-OHM and 1-OHM/MDZ in healthy subjects (HS)

E. Choo, G. Wilkinson, A. Kashuba, 2001 .

Flumazenil reduces midazolam‐induced cognitive impairment without altering pharmacokinetics

A. Nafziger, J. Bertino, M. Rocci, 2002, Clinical pharmacology and therapeutics.

Quantitative assessment of hepatic blood flow using intravenous indocyanine green

Joseph D. Ma, A. Nafziger, J. Bertino, 2008, European Journal of Clinical Pharmacology.

Over‐the‐Counter Progesterone Cream Produces Significant Drug Exposure Compared to a Food and Drug Administration‐Approved Oral Progesterone Product

A. Nafziger, J. Bertino, R. Kulawy, 2005, Journal of clinical pharmacology.